Table 1 ctDNA with an activating mutation that was not present in biopsy samples.

Patient ID	Age	Sex	Stage	EGFR-TKI	Initial response	Mutation in biopsy samples	Mutation of T-type ctDNA	Time point of T-type ctDNA^*	Time point of objective disease progression^*	Time point of last sample^*	Therapies after disease progression
E5	65	F	IV	Gefitinib	PR	Exon 19 deletion	L858R	2	—	19	NA
E6	67	M	IV	Gefitinib	PR	L858R	Exon 19 deletion	12 19	—	131	NA
E7	76	F	IV	Gefitinib	SD	L858R	Exon 19 deletion	6	—	222	NA
E8	68	F	IIIB	Erlotinib	SD	Exon 19 deletion	L858R	7	—	70	NA
1	77	F	IIIA	Erlotinib	PR	L858R	Exon 19 deletion	28	659	1115	Erlotinib (continuation)
2	39	F	IV	Gefitinib	PR	Exon 19 deletion	L858R	14	372	436	Erlotinib
3	80	M	IV	Gefitinib	PR	L858R	Exon 19 deletion	347	296	440	CBDCA
5	69	F	IV	Gefitinib	PR	L858R	Exon 19 deletion	14	383	475	CDDP+PEM
13	66	F	IIIA	Gefitinib	NE	L858R	Exon 19 deletion	28	217	283	Erlotinib
15	56	F	IIIB	Gefitinib	PR	L861Q	Exon 19 deletion	34	335	761	CDDP+PEM
K192	73	F	IV	Gefitinib	PR	L858R	Exon 19 deletion	30	—	747	NA

E5 - E8, the first data set; 1 - K192, the second data set; ^*, days after EGFR-TKI initiation. Patient IDs of the second data set are those used in a previous publication²³ except K192. Abbreviations are as follows: PR, partial response; SD, stable disease; NE not evaluable; NA, not applied; CBDCA, carboplatin; CDDP, cisplatin; PEM, pemetrexed.

Quick links

Search